Compare PRSO & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | XCUR |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 13.7M |
| IPO Year | 2000 | 2017 |
| Metric | PRSO | XCUR |
|---|---|---|
| Price | $0.91 | $2.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 624.2K | 20.3K |
| Earning Date | 05-11-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 81.23 | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,573,000.00 | N/A |
| Revenue This Year | $18.48 | N/A |
| Revenue Next Year | $53.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.77 | $1.71 |
| 52 Week High | $2.37 | $9.50 |
| Indicator | PRSO | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 33.63 |
| Support Level | $0.81 | N/A |
| Resistance Level | $0.95 | $3.50 |
| Average True Range (ATR) | 0.06 | 0.35 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 9.86 | 34.48 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.